ArticleGastroenterology2022
An Exosome-based Transcriptomic Signature for Noninvasive, Early Detection of Patients With Pancreatic Ductal Adenocarcinoma: A Multicenter Cohort Study.
Article in Gastroenterology, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to 3 registered trials, which are not on this map. Cited by 106 papers, 3 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Early Detection of Stomach Cancer With a Liquid Biopsy Based on Exosomal Micro-RNA
Early Detection of Pancreatic Cancer: Prospective Study
Liquid Biopsy Using Exosomal miRNA for Intrahepatic Cholangiocarcinoma Detection
Who cites it
106 citing papers in PubMed, 3 syntheses or guidelines pooled it, 150 citations in OpenAlex.
- The diagnostic and prognostic potential of extracellular vesicles as biomarkers for thyroid cancer: a systematic review.Journal of molecular medicine (Berlin, Germany) · 2025Pooled it
- The role of novel biomarkers in the early diagnosis of pancreatic cancer: A systematic review and meta-analysis.PloS one · 2025Pooled it
- Diagnostic and Prognostic Accuracy of MiRNAs in Pancreatic Cancer: A Systematic Review and Meta-Analysis.Journal of cellular and molecular medicine · 2025Pooled it
- Liquid biopsy for early detection of pancreatic ductal adenocarcinoma.Nature medicine · 2026Article
- Extracellular vesicle biomarkers in pancreatic ductal adenocarcinoma: from bulk detection to single-extracellular vesicle profiling and endoscopic liquid biopsy.Journal of gastroenterology · 2026Review
- Plasmonic Nanoarray Biosensors for Non-Invasive Cancer Diagnostics.Biosensors · 2026Review
- An RNase domain-dependent microRNA detection with DNA-spiked nanocage for accurate cancer diagnosis.Nature communications · 2026Article
- Dynamic remodeling of the pancreas immune landscape in obesity.Nature communications · 2026Article
- LLPS-based classification and a novel prognostic signature reveal NRF1 as a therapeutic target in pancreatic cancer.Cancer cell international · 2026Article
- Extracellular vesicle and particle biomarkers in cancer: a machine learning blueprint for liquid biopsy.Journal of nanobiotechnology · 2026Review
- Machine learning and artificial intelligence in liquid biopsy-based early detection of pancreatic cancer: a scoping review.BJC reports · 2026Review
- Liquid Biopsy Frontiers in Pancreatic Cancer: Insights from Circulating Cell-Free Nucleic Acids.Cells · 2026Review
- EXONERATE-TRaCE: A Liquid Biopsy for Tracking Response to Anti-Epidermal Growth Factor Receptor-Based Therapy in Metastatic Colorectal Cancer.JCO precision oncology · 2026Article
- Comparison of Comprehensive Serum miRNA Sequencing and Apolipoprotein A2 Isoforms for Early Detection of Pancreatic Cancer.Cancers · 2026Article
- Proteomic Profiling of Human Extracellular Vesicles Reveals Diagnostic Biomarkers for Colon Adenocarcinoma.Journal of extracellular vesicles · 2026Article
- Recent advances in machine learning-enhanced extracellular vesicle omics for oncology.Journal of nanobiotechnology · 2026Review
- Detection of plasma EV-associated TRAIL by nanoscale flow cytometry for liver metastasis prediction in PDAC.Advanced biotechnology · 2026Article
- An exosome-based liquid biopsy to predict molecular residual disease for the identification of high-risk patients with stage II-III colorectal cancer: the CLEAR study.Molecular cancer · 2026Observational
- Ultrafast and specific miRNA quantification via single-molecule fluorescence quenching kinetics.Communications biology · 2026Article
- PanMETAI - a high performance tabular foundation model for accurate pancreatic cancer diagnosis via NMR metabolomics.Nature communications · 2026Article
46 more citing papers are in PubMed but not listed here.
Corrections and comments
- Commented on by
Authors and funding
28 authors at 14 institutions in 5 countries.
Funding
Abstract
BACKGROUND &
aimsPancreatic ductal adenocarcinoma (PDAC) incidence is rising worldwide, and most patients present with an unresectable disease at initial diagnosis. Measurement of carbohydrate antigen 19-9 (CA19-9) levels lacks adequate sensitivity and specificity for early detection; hence, there is an unmet need to develop alternate molecular diagnostic biomarkers for PDAC. Emerging evidence suggests that tumor-derived exosomal cargo, particularly micro RNAs (miRNAs), offer an attractive platform for the development of cancer-specific biomarkers. Herein, genomewide profiling in blood specimens was performed to develop an exosome-based transcriptomic signature for noninvasive and early detection of PDAC.
methodsSmall RNA sequencing was undertaken in a cohort of 44 patients with an early-stage PDAC and 57 nondisease controls. Using machine-learning algorithms, a panel of cell-free (cf) and exosomal (exo) miRNAs were prioritized that discriminated patients with PDAC from control subjects. Subsequently, the performance of the biomarkers was trained and validated in independent cohorts (n = 191) using quantitative reverse transcription polymerase chain reaction (qRT-PCR) assays.
resultsThe sequencing analysis initially identified a panel of 30 overexpressed miRNAs in PDAC. Subsequently using qRT-PCR assays, the panel was reduced to 13 markers (5 cf- and 8 exo-miRNAs), which successfully identified patients with all stages of PDAC (area under the curve [AUC] = 0.98 training cohort; AUC = 0.93 validation cohort); but more importantly, was equally robust for the identification of early-stage PDAC (stages I and II; AUC = 0.93). Furthermore, this transcriptomic signature successfully identified CA19-9 negative cases (<37 U/mL; AUC = 0.96), when analyzed in combination with CA19-9 levels, significantly improved the overall diagnostic accuracy (AUC = 0.99 vs AUC = 0.86 for CA19-9 alone).
conclusionsIn this study, an exosome-based liquid biopsy signature for the noninvasive and robust detection of patients with PDAC was developed.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.